Related Experiment Video
Updated: Jul 13, 2026
11:34
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.1K
Personalizing breast cancer staging by the inclusion of ER, PR, and HER2
Sanjay P Bagaria1, Partha S Ray2, Myung-Shin Sim3
1Department of Surgery, Mayo Clinic Florida, Jacksonville.
JAMA Surgery
|December 6, 2013
Summary
Adding triple-negative phenotype (TNP) status to the TNM staging system significantly improves breast cancer prognosis accuracy. This enhancement helps better stratify patients and refine treatment strategies for better outcomes.
Area of Science:
- Oncology
- Biomarker Research
- Cancer Staging
Background:
- Current TNM staging for breast cancer lacks nonanatomic factors like biomarkers.
- Histologic grade and biomarkers are crucial for guiding breast cancer management.
Purpose of the Study:
- To evaluate if incorporating the triple-negative phenotype (TNP) improves TNM staging accuracy for breast cancer prognosis.
- To assess the prognostic value of TNP, defined by absence of ER, PR, and HER2 receptors.
Main Methods:
- Analysis of 1842 patients with invasive ductal breast cancer from 1991-2008.
- Exclusion of patients receiving neoadjuvant therapy or with incomplete staging/biomarker data.
- Categorization of breast cancers by TNM stage and TNP status.
Main Results:
- Triple-negative breast cancer (TNP) survival curves mirrored non-TNP cancers one TNM stage higher.
- TNP status was a significant prognostic variable.
- TNM staging incorporating TNP showed superior prognostic accuracy (P<.001) and reduced early-stage compression by 15%.
Conclusions:
- Nonanatomic factors, exemplified by ER, PR, and HER2 status, enhance breast cancer prognostic accuracy.
- Easily reproducible biomarker assessments can refine cancer staging systems.
- Improved prognostic accuracy aids in more precise breast cancer management.
